Study on Using Iron Oxide to Visualize Tumor Spread in Glioblastoma Patients

1 1 1 1

What is this study about?

This clinical trial is focused on studying glioblastoma, a type of brain cancer. The study will use a special form of iron called iron oxide (E172), which is a concentrate for dispersion for infusion. This means it is prepared in a way that allows it to be given through a vein. The purpose of the study is to see how much glioblastomas spread into healthy brain tissue and whether using ultrasmall superparamagnetic iron oxide particles can help visualize these spreading tumor cells. This could help predict where the tumor might come back.

The study will involve two groups of participants. The first group will include healthy individuals to help determine the right amount of iron oxide needed for clear brain imaging. The second group will consist of patients with glioblastoma. These patients will undergo MRI scans using a new imaging protocol to see how well the iron oxide highlights the tumor and its spread. The study aims to improve the understanding of glioblastoma behavior and enhance imaging techniques to better monitor the disease.

The trial is expected to start recruiting participants in early 2025 and will continue until early 2027. The findings from this study could provide valuable insights into the treatment and monitoring of glioblastoma, potentially leading to better outcomes for patients with this challenging condition.

1 joining the study

Upon joining the study, eligibility is confirmed based on criteria such as being diagnosed with suspected glioblastoma, being between 18-75 years old, and being eligible for neurosurgical resection and/or chemoradiation therapy.

2 initial assessment

An initial assessment is conducted to gather baseline information. This may include medical history review and physical examination.

3 medication administration

The study involves the administration of iron oxide (e172) particles, which are very small magnetic particles. These are given through a method called intravascular use, meaning they are introduced into the bloodstream.

The purpose of these particles is to help visualize tumor cells during imaging procedures.

4 imaging procedures

Magnetic Resonance Imaging (MRI) is performed using a special protocol to capture detailed images of the brain. This includes various sequences such as T1-weighted, T2-weighted, and others.

The goal is to observe how the tumor infiltrates healthy brain tissue and to predict areas where the tumor might return.

5 follow-up assessments

Regular follow-up assessments are conducted to monitor health and gather data on the effectiveness of the imaging techniques.

These assessments may include additional imaging and clinical evaluations.

6 completion of study

The study is expected to continue until January 1, 2027. Upon completion, participants may receive information about the study findings and any implications for their health.

Who Can Join the Study?

Diagnosed with suspected glioblastoma (a type of brain tumor).
Age between 18-75 years.
Eligible for neurosurgical resection (surgery to remove part of the brain) and/or chemoradiation therapy (a combination of chemotherapy and radiation therapy).

Who Cannot Join the Study?

Patients who are not diagnosed with glioblastoma cannot participate. Glioblastoma is a type of brain cancer.
Patients who are under 18 years old cannot participate.
Patients who are over 65 years old cannot participate.
Patients who are pregnant or breastfeeding cannot participate.
Patients who have other serious health conditions that might interfere with the study cannot participate.
Patients who are unable to give informed consent cannot participate. This means they must understand the study and agree to take part.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country	Status
Stichting Radboud University Medical Center	Nijmegen	The Netherlands

Trial status

Country	Status	Recruitment Start
The Netherlands	Not yet recruiting	01.01.2025

Trial locations

Ultrasmall Superparamagnetic Iron Oxide Particles (USPIO) are tiny iron-based particles used in this study to help visualize brain tumors. These particles are designed to be very small so they can move through the bloodstream and reach the brain. When used in magnetic resonance imaging (MRI), they help doctors see the tumor more clearly by highlighting areas where the tumor might be spreading into healthy brain tissue. This can help in predicting where the tumor might come back after treatment.

Investigated diseases:

Glioblastoma

Glioblastoma – Glioblastoma is a type of brain cancer that originates from glial cells, which support nerve cells in the brain. It is known for its aggressive nature and rapid growth. The disease typically begins in the cerebral hemispheres but can occur in other parts of the brain or spinal cord. As it progresses, glioblastoma can infiltrate surrounding healthy brain tissue, making it difficult to remove completely. This infiltration can lead to various neurological symptoms depending on the affected brain areas. The tumor’s growth can cause increased pressure within the skull, leading to headaches, nausea, and other symptoms.

Trial ID:

2024-514013-34-00

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Using Iron Oxide to Visualize Tumor Spread in Glioblastoma Patients

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?